News | November 10, 2021
Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Zydus Wellness Limited has reported consolidated financial results for the period ended September 30, 2021
Cipla has reported consolidated financial results for the period ended September 30, 2021
Torrent Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
ANG Lifesciences India Limited has reported financial results for the period ended September 30, 2021
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
Subscribe To Our Newsletter & Stay Updated
